Compare Weibo Corp (WB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Weibo Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Weibo Corp trades at $7.87 (market cap $1.93B), while State Street SPDR S&P Biotech ETF trades at $159.13. The key difference: Weibo Corp pays a 7.75% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Weibo Corp nearer its low. Which is the better fit depends on your goals.
| WB | XBI | |
|---|---|---|
Market Cap | $1.93B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $12.83 | $164.28 |
52-Week Low | $7.20 | $86.92 |
Enterprise Value | $1.20B | — |
Dividend Yield | 7.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Weibo (WB) trades at $7.74, down 3.01% in the last session, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a low P/E of 5.5 and robust net income margin of 21.15%, while cash flow trends improved in 2025. Recent news highlights Q2 2026 results anticipation and AI developments, but competitive pressures persist.
The outlook is mixed; valuation metrics suggest undervaluation with analyst support, but earnings volatility and market sentiment risks require caution. Opportunities lie in cash flow strength and balance sheet health, while risks include user engagement challenges and macroeconomic headwinds in the social media sector.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
